The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study
- PMID: 39814200
- DOI: 10.1016/j.annonc.2024.12.015
The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study
Abstract
Background: Left-sided pancreatic cancer is associated with worse overall survival (OS) compared with right-sided pancreatic cancer. Although neoadjuvant therapy is currently seen as not effective in patients with resectable pancreatic cancer (RPC), current randomized trials included mostly patients with right-sided RPC. The purpose of this study was to assess the association between neoadjuvant therapy and OS in patients with left-sided RPC compared with upfront surgery.
Patients and methods: This was an international multicenter retrospective study including consecutive patients after left-sided pancreatic resection for pathology-proven RPC, either after neoadjuvant therapy or upfront surgery in 76 centers from 18 countries on 4 continents (2013-2019). The primary endpoint was OS from diagnosis. Time-dependent Cox regression analysis was carried out to investigate the association of neoadjuvant therapy with OS, adjusting for confounders at the time of diagnosis. Adjusted OS probabilities were calculated.
Results: Overall, 2282 patients after left-sided pancreatic resection for RPC were included of whom 290 patients (13%) received neoadjuvant therapy. The most common neoadjuvant regimens were (m)FOLFIRINOX (38%) and gemcitabine-nab-paclitaxel (22%). After upfront surgery, 72% of patients received adjuvant chemotherapy, mostly a single-agent regimen (74%). Neoadjuvant therapy was associated with prolonged OS compared with upfront surgery (adjusted hazard ratio 0.69, 95% confidence interval 0.58-0.83) with an adjusted median OS of 53 versus 37 months (P = 0.0003) and adjusted 5-year OS rates of 47% versus 35% (P = 0.0001) compared with upfront surgery. Interaction analysis demonstrated a stronger effect of neoadjuvant therapy in patients with a larger tumor (Pinteraction = 0.003) and higher serum carbohydrate antigen 19-9 (CA19-9; Pinteraction = 0.005). In contrast, the effect of neoadjuvant therapy was not enhanced for splenic artery (Pinteraction = 0.43), splenic vein (Pinteraction = 0.30), retroperitoneal (Pinteraction = 0.84), and multivisceral (Pinteraction = 0.96) involvement.
Conclusions: Neoadjuvant therapy in patients with left-sided RPC was associated with improved OS compared with upfront surgery. The impact of neoadjuvant therapy increased with larger tumor size and higher serum CA19-9 at diagnosis. Randomized controlled trials on neoadjuvant therapy specifically in patients with left-sided RPC are needed.
Keywords: CA19-9; neoadjuvant therapy; pancreatic adenocarcinoma; pancreatic body/tail; resectable; tumor size.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study.Br J Cancer. 2025 Jul;133(1):76-84. doi: 10.1038/s41416-025-03025-1. Epub 2025 May 6. Br J Cancer. 2025. PMID: 40328917
-
Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.Ann Surg Oncol. 2025 Aug;32(8):5411-5420. doi: 10.1245/s10434-025-17407-5. Epub 2025 May 13. Ann Surg Oncol. 2025. PMID: 40358779
-
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y. BMC Cancer. 2018. PMID: 30594153 Free PMC article.
-
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.Dig Surg. 2019;36(6):455-461. doi: 10.1159/000493466. Epub 2018 Nov 8. Dig Surg. 2019. PMID: 30408790 Review.
-
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.J Surg Oncol. 2021 May;123(6):1432-1440. doi: 10.1002/jso.26384. J Surg Oncol. 2021. PMID: 33831253 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical